

Founded In
1998

Approximately
1300
Employees

13
Global
Locations

8
Marketed
Products

CMO
Bulk Drug
Fill/Finish

\$489M
2016 Total
Revenue



At Emergent BioSolutions our mission is to protect and enhance life.

We are a global life sciences company focused on providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025.

MARKETED PRODUCTS

Vaccines

- ▶ **BioThrax®¹**
Anthrax Vaccine Adsorbed
- ▶ **ACAM2000®¹**
Smallpox (Vaccinia)
Vaccine, Live

Devices

- ▶ **RSDL®¹**
Reactive Skin
Decontamination Lotion Kit
- ▶ **Trobigard™²**
Auto-injector: atropine
sulfate, obidoxime chloride

Antibody Therapeutics

- ▶ **Anthrasil®**
Anthrax Immune Globulin
Intravenous (Human)
- ▶ **Raxibacumab**
Anthrax Monoclonal Antibody
- ▶ **BAT®¹**
Botulism Antitoxin
Heptavalent
(A, B, C, D, E, F, G) – (Equine)
- ▶ **VIGIV^{1,3}**
Vaccinia Immune Globulin
Intravenous (Human)

PIPELINE

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AV7909 (NuThrax™) (Anthrax vaccine adsorbed with CPG 7909)				2018 ^{4*}
FLU-IGIV (Seasonal influenza antibody therapeutic)			2017*	
UV-4B (Dengue antiviral therapeutic)				
ZIKV-VLA1601 (Zika vaccine)		2017-18*		
ZIKV-IG (Zika antibody therapeutic)		2017-18*		
GC-072 (Burkholderia antibacterial therapeutic)				
FILOV (Pan filovirus antibody therapeutic)				
SIAN (Stabilized isoamyl nitrite intranasal spray: acute cyanide poisoning antidote)				

¹ The only available product approved by the U.S. Food and Drug Administration (FDA) for its indication
² Not approved by the FDA or other regulatory agencies; only sold outside of the United States to authorized government buyers
³ Indicated for adverse events associated with the Smallpox vaccine
⁴ Status reflects both clinical and nonclinical development under the FDA Animal Rule
^{*} First subject enrollment target date



PLATFORMS & TECHNOLOGIES




Hyperimmunes

Human and equine plasma products generated for targeted therapy of specific indications



Auto-injector

Platform designed for intramuscular rapid delivery of medical treatments



Antivirals

Broad-spectrum iminosugars to reduce viral infectivity



Antibacterials

Broad-spectrum antibiotics against quinolone-resistant bacterial strains



MVAtor™

Flexible viral vector platform for antigen delivery

RECENT BUSINESS HIGHLIGHTS

- ▶ ACAM2000 business acquired from Sanofi
- ▶ Contract award valued at up to \$25 million to deliver Trobigard to the Department of State
- ▶ Follow-on contract valued at up to \$171 million awarded to supply U.S. Department of Defense with RSDL
- ▶ Contract valued at \$63 million awarded by BARDA to develop treatment for cyanide exposure
- ▶ Awarded \$23 million to develop novel multi-drug auto-injector for U.S. Department of Defense
- ▶ Raxibacumab acquired from GSK
- ▶ Contract modification valued at up to \$53 million received from BARDA for the manufacture of botulism antitoxin
- ▶ Contracts valued at up to \$1 billion awarded by HHS for BioThrax deliveries to the Strategic National Stockpile
- ▶ Contract valued at up to \$1.6 billion awarded by BARDA for advanced development and delivery of NuThrax

AWARDS & RECOGNITION

2017

- ▶ **Chief Executive Officer of the Year**
Daniel J. Abdun-Nabi from the Maryland Tech Council
- ▶ **Corporate Community Leader**
Michigan Governor's Service Awards

2016

- ▶ **Best Stakeholder/Employee Engagement Honorable Mention**
PR Daily's CSR Awards
- ▶ **Best Performing Company in Maryland**
Forbes
- ▶ **Top 100 Fastest Growing Company**
Fortune Magazine
- ▶ **Governor's Service Award for Service and Volunteerism**
Maryland Governor's Office on Service & Volunteerism

MANUFACTURING EXPERTISE

Manufacturing Facilities

- ▶ Baltimore, Maryland (Bayview/CIADM)
- ▶ Baltimore, Maryland (Camden)
- ▶ Canton, Massachusetts
- ▶ Hattiesburg, Mississippi
- ▶ Lansing, Michigan
- ▶ Rockville, Maryland
- ▶ Winnipeg, Manitoba, Canada

Contract Manufacturing Operations

- ▶ All phases of drug development from project origin through fill/finish of final product
- ▶ Currently producing more than 20 commercial products
- ▶ Single-use systems for efficiency and purity with minimal risk of product contamination
- ▶ Support for mammalian, microbial, avian, insect and viral cell lines
- ▶ Fill/finish capabilities include vials and syringes, liquid and lyophilized products

Center for Innovation in Advanced Development and Manufacturing (CIADM)

- ▶ One of three CIADM facilities in the U.S.
- ▶ 112,000 ft² state-of-the-art facility with manufacturing areas, laboratory and office space
- ▶ Public-private partnership
- ▶ Developed with support from BARDA
- ▶ Flexible manufacturing
- ▶ Employs single-use manufacturing technology where applicable
- ▶ Surge capacity readiness

CONTACT INFORMATION

Corporate Headquarters

400 Professional Drive
Suite 400
Gaithersburg, MD 20879 USA
240.631.3200

Investor Inquiries

Robert Burrows
VP, Investor Relations
240.631.3280
BurrowsR@ebsi.com

Media Inquiries

Lynn Kieffer
VP, Corporate Communications
240.631.3391
KiefferL@ebsi.com



LEARN MORE AT ebsi.com

Emergent BioSolutions, Protected by Emergent BioSolutions™, ACAM2000®, Anthrasil®, BAT®, BioThrax®, MVAtor™, NuThrax™, RSDL®, Trobigard™, and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All rights reserved. 10/17

